Insulin therapy and the risk of colorectal cancer in patients with type 2 diabetes: A meta-analysis of observational studies

British Journal of Clinical Pharmacology

Volumn 78, Issue 2, 2014, Pages 301-309

  Bu, Wu Jie ^a   Song, Lei ^a   Zhao, Dan Yi ^a   Guo, Bing ^a   Liu, Jing ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

colorectal cancer; epidemiology; insulin; meta analysis

Indexed keywords

INSULIN; ANTIDIABETIC AGENT;

ARTICLE; ASIA; BODY MASS; CANCER RISK; COCHRANE LIBRARY; COLORECTAL CANCER; DISEASE COURSE; EMBASE; EUROPE; GENDER; HUMAN; INSULIN TREATMENT; MEDLINE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SMOKING; STUDY DESIGN; SYSTEMATIC REVIEW; UNITED STATES; CHEMICALLY INDUCED; COLORECTAL TUMOR; DIABETES MELLITUS, TYPE 2; RISK; STATISTICAL ANALYSIS;

COLORECTAL NEOPLASMS; DATA INTERPRETATION, STATISTICAL; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; OBSERVATIONAL STUDY AS TOPIC; RISK;

EID: 84904883587     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12350     Document Type: Article

References (40)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Faivre J, Bouvier AM, Bonithon-Kopp C,. Epidemiology and screening of colorectal cancer. Best Pract Res Clin Gastroenterol 2002; 16: 187-199.
3. Riedy M,. Preventing colorectal cancer. Adv NPs PAs 2013; 4: 18-21.
4. Whiting DR, Guariguata L, Weil C, Shaw J,. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94: 311-321.
5. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M,. Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011; 378: 31-40.
6. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D,. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33: 1674-1685.
7. Luo W, Cao Y, Liao C, Gao F,. Diabetes mellitus and the incidence and mortality of colorectal cancer: a meta-analysis of 24 cohort studies. Colorectal Dis 2012; 14: 1307-1312.
8. Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR,. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 2009; 373: 2215-2221.
9. Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L, Renehan AG, Diabetes and Cancer Research Consortium. Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia 2012; 55: 1607-1618.
10. Belfiore A, Malaguarnera R,. Insulin receptor and cancer. Endocr Relat Cancer 2011; 18: 125-147.
11. Takahari D, Yamada Y, Okita NT, Honda T, Hirashima Y, Matsubara J, Takashima A, Kato K, Hamaguchi T, Shirao K, Shimada Y, Shimoda T,. Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer. Oncology 2009; 76: 42-48.
12. DeWitt DE, Hirsch IB,. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003; 289: 2254-2264.
13. Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM,. Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab 2012; 97: E1170-1175.
14. Chung YW, Han DS, Park KH, Eun CS, Yoo KS, Park CK,. Insulin therapy and colorectal adenoma risk among patients with Type 2 diabetes mellitus: a case-control study in Korea. Dis Colon Rectum 2008; 51: 593-597.
15. Currie CJ, Poole CD, Gale EA,. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-1777.
16. Hsieh MC, Lee TC, Cheng SM, Tu ST, Yen MH, Tseng CH,. The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res 2012; 2012: 413782.
17. Koro C, Barrett S, Qizilbash N,. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf 2007; 16: 485-492.
18. Onitilo AA, Stankowski RV, Berg RL, Engel JM, Glurich I, Williams GM, Doi SA,. Type 2 diabetes mellitus, glycemic control, and cancer risk. Eur J Cancer Prev 2014; 23: 134-140.
19. Vinikoor LC, Long MD, Keku TO, Martin CF, Galanko JA, Sandler RS,. The association between diabetes, insulin use, and colorectal cancer among Whites and African Americans. Cancer Epidemiol Biomarkers Prev 2009; 18: 1239-1242.
20. Wong P, Weiner MG, Hwang WT, Yang YX,. Insulin therapy and colorectal adenomas in patients with diabetes mellitus. Cancer Epidemiol Biomarkers Prev 2012; 21: 1833-1840.
21. Yang YX, Hennessy S, Lewis JD,. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004; 127: 1044-1050.
22. Campbell PT, Deka A, Jacobs EJ, Newton CC, Hildebrand JS, McCullough ML, Limburg PJ, Gapstur SM,. Prospective study reveals associations between colorectal cancer and type 2 diabetes mellitus or insulin use in men. Gastroenterology 2010; 139: 1138-1146.
23. Carstensen B, Witte DR, Friis S,. Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia 2012; 55: 948-958.
24. Gu Y, Wang C, Zheng Y, Hou X, Mo Y, Yu W, Zhang L, Hu C, Nan H, Chen L, Li J, Liu Y, Huang Z, Han M, Bao Y, Zhong W, Jia W,. Cancer incidence and mortality in patients with type 2 diabetes treated with human insulin: a cohort study in Shanghai. PLoS ONE 2013; 8: e53411.
25. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Oxford: The Cochrane Collaboration, 2011.
26. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010; 8: 336-341.
27. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
28. Aune D, Lau R, Chan DS, Vieira R, Greenwood DC, Kampman E, Norat T,. Nonlinear reduction in risk for colorectal cancer by fruit and vegetable intake based on meta-analysis of prospective studies. Gastroenterology 2011; 141: 106-118.
29. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
30. Woolf B,. On estimating the relation between blood group and disease. Ann Hum Genet 1955; 19: 251-253.
31. Higgins JP, Thompson SG,. Controlling the risk of spurious findings from meta-regression. Stat Med 2004; 23: 1663-1682.
32. Egger M, Davey Smith G, Schneider M, Minder C,. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
33. Begg CB, Mazumdar M,. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
34. American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care 2007; 30: (Suppl 1): S4-S41.
35. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M,. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
36. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
37. Sandhu MS, Dunger DB, Giovannucci EL,. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 2002; 94: 972-980.
38. LeRoith D, Baserga R, Helman L, Roberts CT Jr,. Insulin-like growth factors and cancer. Ann Intern Med 1995; 122: 54-59.
39. Tran TT, Medline A, Bruce WR,. Insulin promotion of colon tumors in rats. Cancer Epidemiol Biomarkers Prev 1996; 5: 1013-1015.
40. Koohestani N, Tran TT, Lee W, Wolever TM, Bruce WR,. Insulin resistance and promotion of aberrant crypt foci in the colons of rats on a high-fat diet. Nutr Cancer 1997; 29: 69-76.